When a teenager is diagnosed with schizophrenia or has a first psychotic episode, the question of medication usually comes up quickly. For most adolescents, an antipsychotic is part of the treatment plan from the start. The decision is rarely simple — it involves weighing the risks of untreated psychosis against the very real side effects of medication, in a young person whose brain and body are still developing. This article explains what the evidence supports, which medications are FDA-approved for adolescents, and what monitoring looks like.
Antipsychotics work in adolescents — but teens are more sensitive to side effects than adults, so medication choice and monitoring matter more.
FDA-approved antipsychotics for adolescents
The U.S. Food and Drug Administration (fda.gov) has approved several second-generation antipsychotics for the treatment of schizophrenia in adolescents, typically ages 13–17. Based on FDA labelling, these include:
- Aripiprazole (Abilify) — ages 13–17
- Olanzapine (Zyprexa) — ages 13–17
- Paliperidone (Invega) — ages 12–17
- Quetiapine (Seroquel) — ages 13–17
- Risperidone (Risperdal) — ages 13–17
- Lurasidone (Latuda) — ages 13–17
For children under 13, almost all antipsychotic use is off-label, and decisions are made very carefully with a child psychiatrist.
How effective are they in teens?
The TEOSS trial (Treatment of Early Onset Schizophrenia Spectrum disorders study), funded by NIMH (nimh.nih.gov), compared molindone, olanzapine, and risperidone in adolescents with first-episode schizophrenia. All three reduced symptoms similarly. Olanzapine caused more weight gain than the others. The trial helped establish that adolescents do respond to antipsychotic treatment, but also that side effects must be a primary consideration.
Why teens are more sensitive to side effects
Compared with adults, adolescents on antipsychotics tend to:
- Gain more weight — sometimes substantially more, especially on olanzapine, quetiapine, and clozapine
- Develop metabolic changes faster — insulin resistance, lipid abnormalities
- Experience more sedation
- Be at higher risk for elevated prolactin (especially with risperidone and paliperidone), which can affect puberty and bone development
- Show movement side effects earlier on first-generation antipsychotics
For these reasons, the AACAP practice parameter recommends starting with antipsychotics that have lower metabolic burden when feasible, using the lowest effective dose, and checking weight, glucose, and lipid panels before starting and at regular intervals.
Monitoring
A reasonable monitoring schedule for a teenager starting an antipsychotic, drawn from AACAP guidance:
- Baseline — height, weight, BMI, blood pressure, fasting glucose, lipid panel, prolactin if relevant, family history of diabetes and cardiovascular disease
- 4 and 8 weeks — weight, blood pressure, side-effect review
- 3 months — repeat metabolic labs
- Every 6 months thereafter — weight, BMI, blood pressure, metabolic labs
- Annually — full review including movement side effects (using a tool such as the AIMS scale)
Conversations to have with the prescriber
- Why this medication, rather than another?
- What is the target dose, and how will we get there?
- What side effects should we watch for?
- How will weight and metabolic health be monitored?
- What is the plan if it does not work in 4–6 weeks?
- How long will my teenager need to take it?
- What about long-acting injectable options?
What about clozapine in teens?
For adolescents whose symptoms do not respond to two adequate trials of other antipsychotics, clozapine is supported by both NIMH research and the AACAP parameter. It carries the same monitoring requirements (weekly blood draws, then less frequent) as in adults. Many adolescents tolerate it well; the impact on positive symptoms can be transformative.
Your teen develops a high fever with stiffness or confusion (possible neuroleptic malignant syndrome), uncontrolled muscle movements, severe sedation they cannot wake from, or thoughts of self-harm. Call 988 (US) or go to an emergency department.
The bottom line for families
The risks of untreated psychosis in a teenager — academic disruption, social withdrawal, substance use, suicide risk, the longer-term toll of a longer duration of untreated psychosis — are real and well-documented. The risks of antipsychotic medication are also real but largely manageable with monitoring and the right medication choice. The conversation between family, teen, and prescriber should be honest and ongoing, with the goal of finding a regimen the young person is willing to take and that lets them rebuild their life.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.